# Agenus Inc. (AGEN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.24, market value $371 million.

## Valuation
- **P/E (trailing): 2.8×**. Agenus Inc. trades at 2.8× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 2.8×**. Each dollar of revenue is priced at 2.8×.
- **EV / EBITDA: 10.1×**. Enterprise value is 10.1× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: -26.6%** (5-yr avg -93.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 36.3%**. The inverse of the P/E: 36.3% of the price is earned each year.

## Profitability
- **Operating margin: 27.3%**. 27.3% of revenue is left after running the business, an exceptional level.
- **Net margin: -2.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: 1.1%**. 1.1% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: -12.5%**. Return on all capital, debt included, is -12.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 40.5%**. Each dollar of assets produces 40.5% of profit.

## Growth
- **Revenue growth (1 yr): 10.4%** (3-yr 5.2%/yr, 5-yr 5.3%/yr). Revenue grew 10.4% over the last year, against 5.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 100.0%**. Earnings per share rose 100.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: 1.0×**. It would take 1.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Agenus Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (2 analysts). 2 analysts cover Agenus Inc.; the consensus is strong_buy, with an average price target of $19.50 (+137% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 92.1%** (YTD 162.4%, 3-mo 155.1%). The shares are up 92.1% over twelve months including dividends.
- **From 52-week high: -6.9%** (204.1% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 1.52** (volatility 118%). Beta of 1.52 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AGEN · Page: https://foliofundamentals.com/stocks/agen

Not investment advice.